TIM-3
T cell
In patients with HR-MDS and AML ,
THE SYSTEM IS CRASHING
The immune system is experiencing a serious error caused by TIM-3 expression . This may be limiting durable outcomes . 1-3
AN UNDERSTANDING OF IMMUNO-THERAPEUTIC APPROACHES FOR MYELOID DISEASES ( SUCH AS IMMUNO-MYELOID THERAPY ) IS EMERGING .
Explore more at TIM3 . com .
AML , acute myeloid leukemia ; HR-MDS , higher-risk myelodysplastic syndrome ; TIM-3 , T cell immunoglobulin and mucin domain-3 .
References : 1 . Wang C , Yang Y , Gao S , et al . Immune dysregulation in myelodysplastic syndrome : clinical features , pathogenesis and therapeutic strategies . Crit Rev Oncol Hematol . 2018 ; 122:123-132 . 2 . Anderson AC , Joller N , Kuchroo VK . Lag-3 , Tim-3 , and TIGIT : co-inhibitory receptors with specialized functions in immune regulation . Immunity . 2016 ; 44 ( 5 ): 989- 1004 . 3 . Kikushige Y , Shima T , Takayanagi S-I , et al . TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells . Cell Stem Cell . 2010 ; 7 ( 6 ): 708-717 .
Novartis Pharm AG |
|
|
|
CH-4002 Basel Switzerland |
© 2021 Novartis |
4 / 21 |
116080 |
Novartis Pharmaceuticals Corporation East Hanover , New Jersey 07936-1080